Clinical Trial Update: A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LY3022855 in combination with durvalumab or tremelimumab in advanced solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Durvalumab (durvalumab)
• LY3022855
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2023-10-16